publicFounded 2014
Intellia Therapeutics
Funding Summary
Total Funding
$1B+
Latest Valuation
~$3B (public market cap)
About
Leading in vivo CRISPR gene editing company with the first clinical data showing CRISPR can edit genes directly inside the human body (NTLA-2001 for ATTR). Co-founded by Jennifer Doudna.
Products
in-vivo-crispr-editing
Recent Developments
Recent developments are auto-populated from tagged articles in the Newsfeed. Browse all news →
Referenced In
NTLA Surges 35% on Phase 3 Gene Editing Readout AnticipationIntellia Therapeutics Joins Major Investor Conference CircuitCitizens Raises Intellia Target to $47 on Gene Editing MilestoneIntellia Stock Jumps 15% After FDA Clears MAGNITUDE Gene Editing TrialsIntellia Stock at Crossroads as CRISPR Pipeline Matures